24/7 Market News Snapshot 29 September, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)
DENVER, Colo., 29 September, 2025 (www.247marketnews.com) – (NASDAQ:SPRC) are discussed in this article.
Today, SciSparc Ltd. (SPRC) experienced a notable surge in its ordinary shares, opening at $4.49 and climbing to an impressive $7.083, marking a remarkable increase of 65.49%. This jump follows a previous session close of $4.28 and highlights robust investor interest, evidenced by a current trading volume of 2.64 million shares. Technical indicators signal a strong bullish sentiment, suggesting that the market is optimistic about further gains in the future.
In a pivotal development, SciSparc is set to enhance its strategic growth through the impending acquisition of its majority-owned subsidiary, MitoCareX Bio Ltd., by N2OFF, Inc. This decision, confirmed by a recent stockholder vote, positions MitoCareX as a wholly-owned subsidiary of N2OFF. MitoCareX is focused on developing innovative therapies for hard-to-treat cancers, targeting essential proteins from the mitochondrial SLC25 protein family.
The acquisition, scheduled for completion in the first half of October 2025, will involve N2OFF purchasing MitoCareX for $700,000 under a securities purchase agreement. Included in this deal is an exchange of outstanding shares for common stock of N2OFF, providing financial incentives for sellers linked to future financing and milestone-driven common stock issuances.
N2OFF has committed to an initial investment of $1,000,000 to support MitoCareX’s operations, indicating confidence in the subsidiary’s potential to advance oncology treatments. As SciSparc continues to focus on its cannabinoid-based pharmaceutical programs, including efforts targeting Tourette Syndrome and Alzheimer’s disease, this collaboration marks a significant step forward in both companies’ dedication to innovation and therapeutic development in the challenging landscape of cancer treatment.